Several databases (Human Protein Atlas and TCGA) show that in 59.6% of GBM cases, PP2A activity is inactivated or dysregulated, especially due to overexpression of its two inhibitors SET and CIP2A. The gene discussed is CIP2A; the disease is glioblastoma.